Early Phase II clinical trial for RK-023 to treat androgenetic alopecia (News-Medical-Net)
->
Lasik surgery in New York has seen the introduction of many more doctor offices and openings – do your research first. I always like to bring you more information on lasik, so here’s another article:
R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company — a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness).
Read full story
